Literature DB >> 6261957

Mutation near the polyoma DNA replication origin permits productive infection of F9 embryonal carcinoma cells.

F K Fujimura, P L Deininger, T Friedmann, E Linney.   

Abstract

F9 mouse embryonal carcinoma cells are resistant to productive infection by wild-type polyoma virus. Continued passage of F9 cells initially infected with wild-type polyoma virus eventually leads to the selection of polyoma virus mutants that are capable of productive infection of undifferentiated F9 cells. Three mutants, PyF101, PyF111 and PyF441, have been plaque-purified and examined. All three PyF mutant DNAs are altered from the wild-type sequence in the Pvu II-4 fragment that spans 67.6 to 70.2 map units on the polyoma genome. PyF441 has a single base change of A to G at 69.6 map units. PyF101 and PyF111 DNAs also contain this point mutation at 69.6 map units. In addition, PyF101 and PyF111 DNAs have exact tandem duplications of 54 and 31 bp, respectively, of sequences encompassing the point mutation, and both copies of the tandem duplication have the point mutation. Other than these changes, no difference exists in the nucleotide sequences of wild-type and PyF mutant DNAs from the BcI I site at 65.6 map units clockwise through the origin of viral DNA replication to the BgI I site at 72.2 map units. DNA infections of F9 cells with wild-type-mutant hybrid DNAs formed by ligation of heterologous combinations of the small and large DNA fragments generated by double digestion with the restriction enzymes BcII and BGI I show that the DNA sequence changes described above are responsible for the ability of the PyF mutants to infect F9 cells.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6261957     DOI: 10.1016/0092-8674(81)90445-1

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  90 in total

1.  The polyoma virus enhancer cannot substitute for DNase I core hypersensitive sites 2-4 in the human beta-globin LCR.

Authors:  K Tanimoto; Q Liu; J Bungert; J D Engel
Journal:  Nucleic Acids Res       Date:  1999-08-01       Impact factor: 16.971

Review 2.  Natural biology of polyomavirus middle T antigen.

Authors:  K A Gottlieb; L P Villarreal
Journal:  Microbiol Mol Biol Rev       Date:  2001-06       Impact factor: 11.056

3.  Biological activities of oligonucleotides spanning the F9 point mutation within the enhancer region of polyomavirus DNA.

Authors:  M Satake; K Furukawa; Y Ito
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

4.  Transcriptional selectivity in early mouse embryos: a qualitative study.

Authors:  C Bonnerot; M Vernet; G Grimber; P Briand; J F Nicolas
Journal:  Nucleic Acids Res       Date:  1991-12       Impact factor: 16.971

Review 5.  Relationship of eukaryotic DNA replication to committed gene expression: general theory for gene control.

Authors:  L P Villarreal
Journal:  Microbiol Rev       Date:  1991-09

6.  Nuclear activity from F9 embryonal carcinoma cells binding specifically to the enhancers of wild-type polyoma virus and PyEC mutant DNAs.

Authors:  F K Fujimura
Journal:  Nucleic Acids Res       Date:  1986-04-11       Impact factor: 16.971

7.  Purification of a mouse nuclear factor that binds to both the A and B cores of the polyomavirus enhancer.

Authors:  Y Kamachi; E Ogawa; M Asano; S Ishida; Y Murakami; M Satake; Y Ito; K Shigesada
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

8.  T-antigen-independent replication of polyomavirus DNA in murine embryonal carcinoma cells.

Authors:  L Dandolo; J Aghion; D Blangy
Journal:  Mol Cell Biol       Date:  1984-02       Impact factor: 4.272

9.  Human polyomavirus JC virus genome.

Authors:  R J Frisque; G L Bream; M T Cannella
Journal:  J Virol       Date:  1984-08       Impact factor: 5.103

10.  Bovine leukemia virus: unique structural features of its long terminal repeats and its evolutionary relationship to human T-cell leukemia virus.

Authors:  N Sagata; T Yasunaga; Y Ogawa; J Tsuzuku-Kawamura; Y Ikawa
Journal:  Proc Natl Acad Sci U S A       Date:  1984-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.